Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06797856 · ClinicalTrials.gov registry record
Measurement of Refractive Error in Pseudophakic Eyes Using an Autorefractor and a Wavefront Aberrometer
A clinical trial, sponsored by Johnson & Johnson Surgical Vision.
- Completed
- Registry status
- 46
- Enrollment target
NCT06797856: Completed study, sponsored by Johnson & Johnson Surgical Vision.
NCT06797856 is a clinical trial that has completed, run by Johnson & Johnson Surgical Vision. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06797856 has completed, sponsored by Johnson & Johnson Surgical Vision.
- COMPLETED
- Registry status
- 46 participants
- Enrollment target
Study Summary
Prospective, single-site, non-interventional, technician masked, randomized (instrument and examiner testing sequences), controlled, bilateral, parallel-group study.
Primary Outcome
* Refractive error centrally (on-axis) and peripherally in both nasal and temporal visual fields * Ocular wavefront measured centrally (on-axis) and peripherally in both nasal and temporal visual fields
Interventions
- DIAGNOSTIC_TEST Refractive Error
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2025-02-17 |
| Est. Completion | 2025-07-09 |
What the finished NCT06797856 record still lists
NCT06797856 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 46 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Refractive Error is the first listed.
NCT06797856 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06797856 about?
NCT06797856 is a clinical study titled "Measurement of Refractive Error in Pseudophakic Eyes Using an Autorefractor and a Wavefront Aberrometer". Prospective, single-site, non-interventional, technician masked, randomized (instrument and examiner testing sequences), controlled, bilateral, parallel-group study.
What is the current status of trial NCT06797856?
This trial is currently completed. The enrollment target is 46 participants. The study started on 2025-02-17. Estimated completion is 2025-07-09.
What interventions are being tested in trial NCT06797856?
The interventions under investigation include: Refractive Error (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06797856?
This trial is sponsored by Johnson & Johnson Surgical Vision, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI